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Background: Transthyretin-associated Familial Amyloid Polyneuropathy (TTR-FAP) is an autosomal dominant
disease caused by the deposition of abnormal transthyretin that results from a gene mutation. Although rare
worldwide, there are descriptions of several endemic foci, such as in Majorca, Balearic Islands, Spain. We aimed at
describing a contemporary series of TTR-FAP patients in Son Llàtzer Hospital in Majorca from an epidemiological
point of view in order to report their main clinical and laboratory characteristics.
Methods: A retrospective, observational study was performed. Medical records from adult patients diagnosed with
TTR-FAP from a single hospital were reviewed.
Results: Out of a total of 107 cases, 75 subjects were included: asymptomatic carriers (52.3%) and symptomatic
patients (47.7%). Mean age was 58.3 years at the time of the study, and 50.7% were men. Mean age at diagnosis
was 49.8 years. In addition, 42 patients (39.2%) had received a liver transplant, and time to liver transplantation was
on average 29.56 months from the initial diagnosis. They all had the Val30Met mutation. The organs of the nervous
system were those most frequently impaired (57.3%), and 83.9% of the symptomatic patients were fully ambulant
(stage 1). Family history was reported in 69.3% of the cases, with the patient’s father being the most commonly
affected relative. Comorbidities were frequent, with high blood pressure being the most common.
Conclusions: Our findings provide additional information on this condition and are useful for describing the
demographic features, clinical presentation, diagnosis, and natural course of TTR-FAP in Majorca.
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Familial amyloid polyneuropathies (FAP) are a group of
systemic amyloidoses caused by the extracellular depos-
ition of insoluble amyloid fibrils. Three main types of
FAP have been described, based on the abnormal amyl-
oid precursor protein resulting from a gene mutation
(transthyretin [TTR], apolipoprotein A-1, or gelsolin)
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reproduction in any medium, provided the orform, with the Val30Met mutation in the TTR gene be-
ing by far the most common variant (accounting for
about 50% of cases worldwide). It is virtually the only
one in some countries, such as Portugal and Sweden [2],
although at present 113 amyloidogenic mutations have
been described in the TTR gene [1-3]. The abnormal
TTR protein is mainly produced in the liver and to a
lesser extent in the choroid plexus and retina.
Transthyretin-associated familial amyloid polyneurop-
athy (TTR-FAP) is a life-threatening disease transmittedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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tion of TTR-FAP is a progressive nerve length-dependent,
sensory-motor polyneuropathy, which usually begins
with loss of thermal and pain sensation in the feet and
slowly ascends up the limbs. This is then followed by
autonomic manifestations and motor dysfunction or
impairment. The progression of the disease is usually
described as going through 3 stages according to the
symptoms and signs shown by the patients. Stage 1 is
characterized by mild motor dysfunction/impairment
of the lower extremities, moderate autonomic manifes-
tations, no or minimum impairment in daily activities,
and full ambulation. Stage 2 is characterized by mild-to-
moderate motor dysfunction/impairment of the lower or
upper extremities, mild autonomic manifestations, signifi-
cant impairment in daily activities, and the need for help in
ambulation. Lastly, stage 3 is described as severe motor
dysfunction/impairment of the lower or upper extremities,
severe autonomic manifestations, profound impairment in
daily activities, and confinement to a wheelchair [4]. Diag-
nosis is based on family history, neurographic evidence of
polyneuropathy, detection of mutated TTR or DNA in the
blood, and identification of amyloid deposits in the tissues
(mainly in intestinal, nerve, salivary gland or abdominal
fat biopsies). The disease is occasionally diagnosed in
sporadic cases with no known family history. Immuno-
labeling or mass spectroscopy-based proteomic ana-
lysis can be useful in identifying the amyloid type, but
a TTR/DNA test is mandatory [1]. Early- and late-onset
presentations have been described, with late-onset presen-
tations showing a slower progression and fewer autonomic
symptoms. TTR-FAP is usually fatal within 10 to 13 years
of the first symptoms [5-7].
Liver transplantation provides a useful and specific
therapy for TTR-FAP by allowing for the suppression of
the main source of the mutant TTR; it prevents neur-
opathy progression in approximately 70% of cases with
Val30Met mutation on a long-term basis [8,9].
In November 2011, the European Medicines Agency
[10] approved tafamidis meglumine, a small molecule
that stabilizes and inhibits the dissociation of circulating
TTR tetramers, thus preventing the deposition and for-
mation of the abnormal TTR fibrils, for TTR-FAP
Val30Met patients with stage-1 polyneuropathy, and it
seems to be very promising [11,12].
TTR-FAP was initially described by Andrade in 1952
in Póvoa de Varzim, Portugal [13], and has subsequently
been reported in several other European countries such
as Sweden [14,15], as well as in countries like Japan
[16,17] and Brazil [18,19], among others. It is a relatively
rare disease worldwide, although it has a relatively high
prevalence in some specific areas. A prevalence of 151/
100,000 inhabitants has been reported in some areas in
northern Portugal (including Póvoa de Varzim, wherethe first cases were discovered) [20] and of 104/100,000
inhabitants in northern Sweden [14]. The reported
prevalence in Japan is 1.5/100,000 [16], and data from
Cyprus suggest a prevalence of 3.72/100,000 [21].
In Spain, a significant area was found to be Majorca in
the Balearic Islands. According to Munar-Qués et al.
[22,23], the rate of prevalence amounts to 5/100,000 in-
habitants in Majorca and 1/100,000 in Minorca, also a
Balearic Island. TTR-FAP has also been described in
other areas in Spain, including Valverde del Camino
(Huelva), the Safor area (Valencia), Barcelona, Cantabria
[24-26], and Vigo (Galicia) [25]. However, the number of
patients in these areas is low. In Majorca the first case
was described in 1976; subsequently the diagnosis of
TTR-FAP was also clinically detected in 15 additional
patients [22]. The disease could have arrived in Majorca
from Portugal as a founder mutation in the 13th or 14th
centuries, or it could have appeared independently in
Majorca, as well as in other parts of the world. In 2005,
a series of 102 confirmed patients from Majorca was
well described by Munar-Qués et al. [27]. According to
their conclusions, TTR-FAP seems to now be a growing
public health problem in the Balearic Islands owing to
its relatively high prevalence, together with its significant
social and clinical impact.
We aimed at describing a contemporary series of
TTR-FAP patients followed at Son Llàtzer Hospital,
Majorca, from an epidemiological point of view and at
reporting their clinical and laboratory characteristics.
Methods
A retrospective, observational study was performed. Med-
ical records from all adult (≥ 18 years old) patients who
met the following inclusion criteria: being diagnosed with
TTR-FAP at Son Llàtzer Hospital (a 350-bed community
center located in Palma de Majorca, Spain). The study
period ran from January 1, 2001 to January 13, 2012, at
which point the recorded data were reviewed. We de-
scribed both the symptomatic patients and the asymp-
tomatic carriers at the time of diagnosis. The cohort of
TTR-FAP patients that underwent liver transplantation
was also described.
Demographic details (age, sex, occupational status)
and clinical data (family history, type of mutation, and
disease stage) were obtained. The results were analyzed
by comparing asymptomatic carriers to symptomatic pa-
tients. As supplemental data we also recorded health
care resource utilization from and at diagnosis.
Diagnostic criteria included: presence of TTR muta-
tion (both in symptomatic patients and asymptomatic
carriers).
Additional tests were performed in symptomatic pa-
tients: electromyogram to confirm the presence of mixed
polyneuropathy; tissue biopsy to detect amyloid deposits;
Table 1 Demographic data of subjects included in the
study at TTR-FAP diagnosis
Variable Number* Percentage Mean ± SD Range
Sex (n = 75)
Men 38 50.7
Women 37 49.3
Age, years (n = 75) 58.33 ± 16.13 28–92
Occupational




Weight, kg (n = 24) 67.00 ± 13.05 35–87
Mean age
at diagnosis,
years (n = 54)
49.8 ± 17.33 13–81
*Total number of patients analyzed; some patients did not report all data.
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ECG) when cardiac involvement was suspected; and
lastly, eye exam when appropriate.
Data confidentiality was respected when decoupling
personal data. The study was classified by the Spanish
Agency of Medicines and Medical Devices and was
approved by the Independent Ethics Committee of Son
Llàtzer Hospital.
Statistical analysis: Pearson’s chi-squared test or Fisher’s
exact test were used for categorical data. Continuous
variables were analyzed using Student’s t-test or one-way
analysis of variance (ANOVA) (or Mann–Whitney U test
for non-parametric variables). A p-value of < 0.05 was used
to show statistically significant associations. All statistical
analyses were based on SPSS ver. 17.0 or later.
Results
A total of 107 cases with heterozygote TTR-Val30Met
pathogenic mutations were diagnosed with TTR-FAP at
Son Llàtzer Hospital in the study period running from
January 2001 to January 2012. We have epidemiological
and clinical data from 75 cases of asymptomatic carriers
and symptomatic patients that were included in this
study, and the remaining 42 patients received a liver
transplantation.
Description of asymptomatic carriers and symptomatic
patients
All of the subjects had the Val30Met mutation. Mean
age was 58.33 ± 16.13 years (range from 28 to 92), and
38 (50.7%) were men (Figure 1) with a mean age at
diagnosis of 49.8 ± 17.33 years (range from 13 to 81).
Mean life expectancy without liver transplantation was
7.4 years. When assessing for this analysis (2011), we did
not report all data, but 36 of 57 subjects (63.2%) had an
active employment status. The rest of the demographic
data are shown in Table 1.
At diagnosis (we have data for 65 subjects), there were
34 (52.3%) asymptomatic carriers and 31 (47.7%)Figure 1 TTR-FAP related in Son Llàtzer Hospital (Majorca)
comparison of asymptomatic carriers and symptomatic patients.symptomatic patients. Clinical stage for those symptom-
atic patients at diagnosis was as follows: stage 1 (fully
ambulant) for 26 patients (83.9%); stage 2 (needing help
with ambulation) for 4 patients (12.9%); and stage 3
(confined to wheelchair) for 1 patient (3.2%) (Figure 2).
A family tree following the disease was performed for
all patients and we found a family history of TTR-FAP
in 52 cases (69.3%), with subjects’ fathers being the most
commonly affected relative. Comorbidities at initial diag-
nosis were frequent 23 (30.7%), with high blood pressure
being the most common, found in 18 subjects (24.0%).
The rest of clinical data, including specific family history,
comorbidities, and initial organ involvement, are shown
in Table 2.
All subjects were diagnosed with a TTR/DNA/genetic
test. Moreover, additional tests were performed in symp-
tomatic patients: electromyogram to rule out the presence
of mixed polyneuropathy; biopsy to try to detect tissue
amyloid deposits; echocardiogram or Holter monitoring
(24-hour ECG) when cardiac involvement was suspected;
and ophthalmic exam when appropriate (Figure 3).
In the comparison between asymptomatic carriers and
symptomatic patients, we found statistically significant
differences in mean age at diagnosis (54 vs. 44 years;
p < 0.05) and also for active employment status (75.8%
vs. 50.0%; p < 0.01). In contrast, we found no statisti-
cally significant differences in mean age. Comorbid dis-
ease profile was similar in both groups.
Patients with liver transplantation
During the data analysis, liver transplantation had
already been performed in 42 patients (39.2%). Not
all the patients could undergo liver transplantation,
mainly owing to advanced age, contraindication (co-
morbidities), or because they were at stage 3 of the
Figure 2 Clinical stage in symptomatic patients at diagnosis.
Table 2 Clinical data of patients included in the study at
TTR-FAP diagnosis
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transplantation waiting list was 29.56 months (range
from 16.72 to 37.88).
After transplantation, 34 patients (80.9%) showed no
disease progression; 23 (54.7%) needed no help with am-
bulation; and most patients (35, or 83.3%) stated that
they were satisfied with their therapy (transplantation).
The post-transplantation course was generally good,
with a relatively high proportion of patients being stable
and with many subjects having an active employment
status (77.8% of patients were able to resume their usual
working activity).Grandfather/grandmother 3 5.8
Uncle/aunt 16 30.8
Sibling 23 44.2
Other (cousin, niece, nephew, etc.) 26 50.0
Unknown 15 20
Comorbidities
Any comorbidity 23 30.7
High blood pressure 18 24.0
Dyslipidemia 7 9.3
Diabetes mellitus 3 4.0
Kidney failure 3 4.0
Smoking 3 4.0
Obesity 2 2.7
Heart failure 1 1.3
Initial organ involvement
Nervous system 43 57.3
Gastrointestinal tract 11 14.7
Erectile dysfunction 4 5.3
Cardiovascular 3 4.0
Kidneys 3 4.0Discussion
Our findings, which are based on a relatively large series
from a local community hospital in Majorca, provide
additional information on this condition and are useful
for describing the demographic features, clinical presen-
tation, diagnosis, and natural course of TTR-FAP in the
Majorca area, a significant endemic focus.
Age of onset has not been consistent in all reported
series (Figure 4). Our findings (mean age at diagnosis of
49.8 years) are similar to previously reported data from
Majorca (age of onset of 45.7 years) [27], as well as to
those from some other Mediterranean areas, like Cyprus
(46 years) [21]. An earlier age of onset has been found in
the main endemic areas in Portugal (33.5 years) [20],
Japan (35.6 years) [16], and Brazil (32 years) [18],
whereas a later age of onset has been reported in north-
ern Sweden (56.7 years) [15]. In contrast, an even later
age of onset (61 years) has been reported in sporadic
cases in a series from a non-endemic area [28]. Taking
into account that the causal mutation is probably the
same in Portugal and Majorca, and that patients who are
not aware of relatives who had the disease (sporadic
Figure 3 Additional tests performed.
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ence in age of onset between Portuguese and Majorcan
cases could possibly be owing to environmental or epi-
genetic factors.
Although a male predominance has been previously
reported in Majorca (62% versus 38%) [27], our results
show a ratio of 51% to 49%. Similar findings have been
reported in some other areas, including Brazil (45% to
55%) [18] and Cyprus (44% to 56%) [21]. A later age of
onset in women has been described in Portugal [20] and
Brazil [18], whereas no differences based on gender were
found in Sweden [15], Cyprus [21], or the previous Ma-
jorcan series [27]. Our findings confirm a similar age of
onset in both men and women.
Clinical data from our series show a high proportion
of patients with a positive family history, mostly owing
to the father. As expected, the existence of a family his-
tory was more common in asymptomatic carriers. Such
individuals had also an earlier diagnosis. A large number
of symptomatic patients received a liver transplant, withFigure 4 Mean age of onset or diagnosis of TTR-FAP in several seriesmean time to receiving a liver transplant being just
slightly longer than 2.5 years from the patient’s diagno-
sis. Data on employment activity are scarce in previous
studies, and our findings are particularly relevant for
demonstrating the real impact of the disease on a pa-
tient’s life.
Weaknesses
This is the first TTR-FAP epidemiological study to in-
clude both clinical and work productivity data during
disease progression. The isolated nature of TTR-FAP
and its being limited to a specific geographical area
make it difficult to extrapolate results. In addition, limi-
tations stemming from the retrospective nature of this
study are also applicable.
Conclusions
TTR-FAP is a life-threatening neurodegenerative disease
that constitutes a public health problem in Majorca, with
a disease focus growing mainly due to TTR-FAP is being[14,16,20-22].
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The clinical characteristics of our series are similar to
those previously reported in the literature, especially in
Mediterranean areas, but with a slightly older age at
onset and relatively higher neurological and digestive in-
volvement at presentation. Because TTR-FAP is a multi-
pathological disease, in Majorca a multidisciplinary group
has been created that includes experts in internal medi-
cine, neurology, cardiology, gastroenterology, ophthalmol-
ogy and pathology, thereby enabling a quicker assessment
of disease involvement at presentation. This multidiscip-
linary approach will probably decrease the age of onset in
Majorca in further studies. The proportion of symptom-
atic TTR-FAP patients in our series who underwent liver
transplantation seems relatively high (56%) compared with
other countries.
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